谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

A Phase II Study of Efficacy and Safety of the MEK Inhibitor Tunlametinib in Patients with Advanced NRAS-mutant Melanoma

Xiaoting Wei,Zhengyun Zou,Weizhen Zhang,Meiyu Fang,Xiaoshi Zhang,Zhiguo Luo,Jing Chen,Gang Huang,Peng Zhang,Ying Cheng,Jiwei Liu,Jiyan Liu,Junping Zhang,Di Wu,Yu Chen, Xiaobiao Ma,Hongming Pan,Renbing Jiang,Xinlan Liu,Xiubao Ren,Hongqi Tian,Zhongwei Jia, Jun Guo, Lu Si

EUROPEAN JOURNAL OF CANCER（2024）

引用 0|浏览63
暂无评分
关键词
Melanoma,NRAS mutation,MEK inhibitor,tunlametinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要